Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
3.265
+0.075 (2.35%)
Apr 29, 2025, 1:10 PM EDT - Market open
Savara Employees
Savara had 59 employees as of December 31, 2024. The number of employees increased by 22 or 59.46% compared to the previous year.
Employees
59
Change (1Y)
22
Growth (1Y)
59.46%
Revenue / Employee
n/a
Profits / Employee
-$1,625,102
Market Cap
687.20M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
SVRA News
- 8 days ago - Savara: Make-It-Or-Break-It Molbreevi BLA Filing - Seeking Alpha
- 17 days ago - Savara Announces New Employment Inducement Grant - Business Wire
- 21 days ago - Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences - Business Wire
- 4 weeks ago - Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update - Business Wire
- 4 weeks ago - Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital - Business Wire
- 4 weeks ago - Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Business Wire
- 6 weeks ago - Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025 - Business Wire
- 7 weeks ago - Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Business Wire